Ionis Pharmaceuticals annual operating margin
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ionis Pharmaceuticals's operating margin was −40.45% for fiscal 2025.
View full Ionis Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −40.45% | +26.93 pp |
| 2024 | 2024-12-31 | −67.37% | −22.46 pp |
| 2023 | 2023-12-31 | −44.91% | +24.93 pp |
| 2022 | 2022-12-31 | −69.84% | −66.11 pp |
| 2021 | 2021-12-31 | −3.72% | +19.87 pp |
| 2020 | 2020-12-31 | −23.60% | −56.19 pp |
| 2019 | 2019-12-31 | 32.59% | +42.83 pp |
| 2018 | 2018-12-31 | −10.23% | −16.27 pp |
| 2017 | 2017-12-31 | 6.04% | +11.45 pp |
| 2016 | 2016-12-31 | −5.41% | +21.30 pp |
| 2015 | 2015-12-31 | −26.70% | −4.42 pp |
| 2014 | 2014-12-31 | −22.29% | +12.79 pp |
| 2013 | 2013-12-31 | −35.08% | +32.46 pp |
| 2012 | 2012-12-31 | −67.54% | +4.22 pp |
| 2011 | 2011-12-31 | −71.76% | −27.18 pp |
| 2010 | 2010-12-31 | −44.58% | −21.93 pp |
| 2009 | 2009-12-31 | −22.65% | −10.46 pp |
| 2008 | 2008-12-31 | −12.18% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −38.18% | −69.11 pp |
| Q1 2026 | 2026-03-31 | −47.72% | +63.87 pp |
| Q4 2025 | 2025-12-31 | −105.47% | −56.56 pp |
| Q3 2025 | 2025-09-30 | −102.21% | +8.88 pp |
| Q2 2025 | 2025-06-30 | 30.93% | +60.27 pp |
| Q1 2025 | 2025-03-31 | −111.59% | +13.53 pp |
| Q4 2024 | 2024-12-31 | −48.91% | −47.02 pp |
| Q3 2024 | 2024-09-30 | −111.09% | −11.74 pp |
| Q2 2024 | 2024-06-30 | −29.34% | +18.53 pp |
| Q1 2024 | 2024-03-31 | −125.12% | −37.66 pp |
| Q4 2023 | 2023-12-31 | −1.89% | +135.07 pp |
| Q3 2023 | 2023-09-30 | −99.35% | −62.32 pp |
| Q2 2023 | 2023-06-30 | −47.87% | +16.04 pp |
| Q1 2023 | 2023-03-31 | −87.45% | −46.93 pp |
| Q4 2022 | 2022-12-31 | −136.95% | −187.09 pp |
| Q3 2022 | 2022-09-30 | −37.03% | +27.48 pp |
| Q2 2022 | 2022-06-30 | −63.92% | −5.89 pp |
| Q1 2022 | 2022-03-31 | −40.52% | +41.89 pp |
| Q4 2021 | 2021-12-31 | 50.14% | +57.94 pp |
| Q3 2021 | 2021-09-30 | −64.50% | −41.68 pp |
| Q2 2021 | 2021-06-30 | −58.03% | −22.47 pp |
| Q1 2021 | 2021-03-31 | −82.41% | −36.57 pp |
| Q4 2020 | 2020-12-31 | −7.81% | −60.61 pp |
| Q3 2020 | 2020-09-30 | −22.82% | −24.33 pp |
| Q2 2020 | 2020-06-30 | −35.56% | −24.07 pp |
| Q1 2020 | 2020-03-31 | −45.83% | −86.73 pp |
| Q4 2019 | 2019-12-31 | 52.80% | +47.19 pp |
| Q3 2019 | 2019-09-30 | 1.50% | +14.28 pp |
| Q2 2019 | 2019-06-30 | −11.49% | +31.21 pp |
| Q1 2019 | 2019-03-31 | 40.89% | +43.18 pp |
| Q4 2018 | 2018-12-31 | 5.61% | +9.31 pp |
| Q3 2018 | 2018-09-30 | −12.77% | −22.33 pp |
| Q2 2018 | 2018-06-30 | −42.70% | −48.45 pp |
| Q1 2018 | 2018-03-31 | −2.29% | −19.11 pp |
| Q4 2017 | 2017-12-31 | −3.70% | −39.79 pp |
| Q3 2017 | 2017-09-30 | 9.56% | −4.96 pp |
| Q2 2017 | 2017-06-30 | 5.74% | +132.93 pp |
| Q1 2017 | 2017-03-31 | 16.83% | +165.04 pp |
| Q4 2016 | 2016-12-31 | 36.09% | +158.14 pp |
| Q3 2016 | 2016-09-30 | 14.52% | +112.52 pp |
| Q2 2016 | 2016-06-30 | −127.18% | −164.25 pp |
| Q1 2016 | 2016-03-31 | −148.21% | −133.30 pp |
| Q4 2015 | 2015-12-31 | −122.05% | −133.92 pp |
| Q3 2015 | 2015-09-30 | −98.00% | −49.22 pp |
| Q2 2015 | 2015-06-30 | 37.07% | +48.72 pp |
| Q1 2015 | 2015-03-31 | −14.91% | +90.44 pp |
| Q4 2014 | 2014-12-31 | 11.88% | +58.88 pp |
| Q3 2014 | 2014-09-30 | −48.78% | +59.36 pp |
| Q2 2014 | 2014-06-30 | −11.65% | +9.16 pp |
| Q1 2014 | 2014-03-31 | −105.35% | −109.10 pp |
| Q4 2013 | 2013-12-31 | −47.00% | +84.43 pp |
| Q3 2013 | 2013-09-30 | −108.14% | +133.61 pp |
| Q2 2013 | 2013-06-30 | −20.81% | −28.62 pp |
| Q1 2013 | 2013-03-31 | 3.75% | +83.18 pp |
| Q4 2012 | 2012-12-31 | −131.43% | −73.98 pp |
| Q3 2012 | 2012-09-30 | −241.76% | −134.02 pp |
| Q2 2012 | 2012-06-30 | 7.81% | +64.45 pp |
| Q1 2012 | 2012-03-31 | −79.43% | −3.26 pp |
| Q4 2011 | 2011-12-31 | −57.45% | +2.57 pp |
| Q3 2011 | 2011-09-30 | −107.74% | −76.48 pp |
| Q2 2011 | 2011-06-30 | −56.64% | +22.80 pp |
| Q1 2011 | 2011-03-31 | −76.17% | −59.86 pp |
| Q4 2010 | 2010-12-31 | −60.02% | −21.19 pp |
| Q3 2010 | 2010-09-30 | −31.26% | −15.68 pp |
| Q2 2010 | 2010-06-30 | −79.45% | — |
| Q1 2010 | 2010-03-31 | −16.31% | — |
| Q3 2009 | 2009-09-30 | −38.83% | — |
| Q2 2009 | 2009-06-30 | −15.57% | — |
Over the last five reported fiscal years, Ionis Pharmaceuticals's operating margin decreased from −23.60% to −40.45%, a change of −16.85 percentage points. The latest reported quarter, Q2 2026, shows −38.18%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals filings at SEC.gov ↗